Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

731.96 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Nvidia's $46.7 Billion Quarter Shows the AI Trade Is Alive and Well -- With Caveats
Here's why investors aren't sure what to make of Nvidia earnings. 
Via The Motley Fool
Topics Artificial Intelligence
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
The Unsettling Dance: Robust Growth and Stubborn Inflation Challenge the Fed's Resolve
The U.S. economy currently navigates an intriguing, yet precarious, path as hypothetical Q2 2025 data suggests a robust rebound in Gross Domestic Product (GDP) growth. This economic buoyancy, however,... 
Via MarketMinute
Topics Bonds Economy Energy
Eli Lilly’s Weight-Loss Star Mounjaro Paused In UK Until September Ahead Of Massive Price Jump
Via Stocktwits
Analyst Expectations For Eli Lilly's Future
 
Via Benzinga
Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Stock Of The Day: Another Breakout For Eli Lilly?
Shares of Eli Lilly (LLY) are testing a resistance level. If they can break through this resistance, a large more higher may follow. 
Via Benzinga
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus. 
Via Benzinga
This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?
Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop... 
Via Stocktwits
2 Growth Stocks That Could Be Worth $1 Trillion in 5 Years
These two longtime market leaders should continue to perform well. 
Via The Motley Fool
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure
Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. 
Via Investor's Business Daily
The Invesco QQQ Trust Has a Glaring Flaw by Excluding This "Ten Titans" Stock and 3 Other Megacap Growth Stocks. Here's an ETF That Corrects the Error.
Investors looking for top growth stocks on the Nasdaq and NYSE may want to consider alternatives to the Invesco QQQ. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears
Patients in UK struggle to obtain Mounjaro drug due to high demand, sharp price increase. Shortages causing stress and health risks. 
Via Benzinga
Stevens Capital Closes Out Position in Eli Lilly
Via The Motley Fool
2 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
It doesn't take much to get your money to start working for you on Wall Street. 
Via The Motley Fool
Market Movers: Unpacking the Forces Behind Recent Stock Swings
The financial markets have been a dynamic arena recently, showcasing significant and often dramatic movements in individual stock valuations. These shifts are not random but are deeply rooted in... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
The Phoenix Market: How Wall Street Defied the "Trump Slump" to Soar to New Highs
The year 2025 has etched itself into financial history as a testament to the stock market's extraordinary resilience. After a tumultuous April and May, dubbed the "Trump Slump," which saw significant... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
Veeva Makes A Bearish Move On One Pockmark In Its Quarterly Report
The company beat second-quarter expectations, with the exception of one key metric. 
Via Investor's Business Daily
MongoDB To Rally Around 63%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
 
Via Benzinga
New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight
Eli Lilly's Phase 3 trial shows Verzenio improves survival in high-risk early breast cancer, with Q2 revenue up 12% to $1.49 billion. 
Via Benzinga
Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)
Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock. 
Via The Motley Fool
Topics Economy World Trade
Why Novo Nordisk Stock Tumbled on Tuesday
A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy. 
Via The Motley Fool
Why Eli Lilly Stock Trounced the Market on Tuesday
The pharma giant advanced a medication that could be extremely competitive in a high-profile segment. 
Via The Motley Fool
Russell 2000 Hits 9-Month Highs, Bitcoin Drops Below $110,000: What's Moving Markets Tuesday?
Investors are watching small caps heat up on an otherwise slow Tuesday morning, with the Russell 2000 climbing 1% and outpacing its larger peers, amid growing bets on a Fed rate cut next month. 
Via Benzinga
Topics Economy
EchoStar, Energy Fuels, Eli Lilly, Hut 8, Nio: Stocks Making The Biggest Moves Today
Via Stocktwits
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway. 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Rep. Jonathan Jackson Has Bought Up to $390K Worth Of Amazon.com Stock: Here's What You Should Know
 
Via Benzinga
As the Market Rotates, This Healthcare ETF Is Leading the Way
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure. 
Via MarketBeat
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.